First-line treatment for stomach cancer with high AFP
Part of Cancer, Digestive system clinical trials.
This study tests a combination of three drugs (sintilimab, apatinib, and chemotherapy called SOX) as the first treatment for stomach cancer that has spread. It's specifically for tumors that have high AFP levels, and the goal is to see if this combination can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have advanced or spread stomach cancer (cancer that cannot be cured with surgery).
- Your cancer is HER2-negative (HER2 is a protein that some cancers make).
- Your blood test shows a high level of AFP, a protein that may be linked to this type of cancer.
- You have not had any previous chemotherapy or other systemic treatment for your cancer.
- You are able to take care of yourself (ECOG 0 or 1) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs — an immunotherapy (sintilimab), a targeted therapy (bevacizumab), and chemotherapy — for a specific type of stomach cancer that produces high AFP and has spread to the liver. The goal is to see if this treatment can shrink tumors enough to make them removable by surgery.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (apatinib) and a chemotherapy drug (irinotecan hydrochloride) for people with a rare type of advanced stomach cancer called AFP-producing gastric cancer. It is for patients whose cancer did not respond to previous immunotherapy combined with chemotherapy.
This trial tests a combination of two targeted drugs (adebrelimab and apatinib) with standard chemotherapy (SOX regimen) before surgery for gastric cancer that cannot be removed right away. The goal is to shrink the tumor enough to make surgery possible.
This trial tests a new combination of drugs for advanced stomach cancer that has not been treated before. The goal is to see if adding a cholesterol-lowering drug to standard chemotherapy and immunotherapy can help shrink tumors and improve outcomes.
This trial tests a combination of two drugs (one targeted therapy and one immunotherapy) given with chemotherapy before and after surgery for stomach cancer that hasn't spread far. The goal is to see if this approach can improve outcomes for people with locally advanced disease.
This phase 3 trial tests adding the targeted drug apatinib to a standard combination of sintilimab (immunotherapy) and chemotherapy (SOX regimen) given before surgery for a specific type of stomach or gastroesophageal junction cancer (intestinal type, HER2-negative). The goal is to see if the three-drug combination works better than the two-drug combination in shrinking the tumor and improving outcomes before surgery.
Hear when a new AFP Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.